307 related articles for article (PubMed ID: 37575762)
1. The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review.
Salazar-Barragan M; Taub DR
Cureus; 2023 Jul; 15(7):e41697. PubMed ID: 37575762
[TBL] [Abstract][Full Text] [Related]
2. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
3. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
[TBL] [Abstract][Full Text] [Related]
4. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
[TBL] [Abstract][Full Text] [Related]
5. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
[TBL] [Abstract][Full Text] [Related]
6. CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy.
Crow H; Bengtson C; Shi X; Graves L; Anabtawi A
J Clin Transl Endocrinol; 2022 Dec; 30():100307. PubMed ID: 36217440
[TBL] [Abstract][Full Text] [Related]
7. Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis.
Taelman V; Declercq D; Van Biervliet S; Weygaerde YV; Lapauw B; Van Braeckel E
Clin Nutr ESPEN; 2023 Dec; 58():73-78. PubMed ID: 38057039
[TBL] [Abstract][Full Text] [Related]
8. Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis.
Chan CL; Granados A; Moheet A; Singh S; Vigers T; Arbeláez AM; Yi Y; Hu S; Norris AW; Ode KL
J Clin Transl Endocrinol; 2022 Dec; 30():100311. PubMed ID: 36620757
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
10. Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.
Grancini V; Gramegna A; Zazzeron L; Alicandro G; Porcaro LL; Piedepalumbo F; Lanfranchi C; Daccò V; Orsi E; Blasi F
Diabetes Metab; 2023 Sep; 49(5):101466. PubMed ID: 37536552
[TBL] [Abstract][Full Text] [Related]
11. Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.
Lurquin F; Gohy S; Hermans MP; Preumont V
J Clin Transl Endocrinol; 2023 Sep; 33():100320. PubMed ID: 37448650
[TBL] [Abstract][Full Text] [Related]
12. Preservation of β-cell Function in Pancreatic Insufficient Cystic Fibrosis With Highly Effective CFTR Modulator Therapy.
Flatt AJ; Sheikh S; Peleckis AJ; Alvarado P; Hadjiliadis D; Stefanovski D; Gallop RJ; Rubenstein RC; Kelly A; Rickels MR
J Clin Endocrinol Metab; 2023 Dec; 109(1):151-160. PubMed ID: 37503734
[TBL] [Abstract][Full Text] [Related]
13. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.
Jordan KD; Zemanick ET; Taylor-Cousar JL; Hoppe JE
Expert Rev Respir Med; 2023 Feb; 17(2):97-108. PubMed ID: 36803356
[TBL] [Abstract][Full Text] [Related]
14. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.
Kapouni N; Moustaki M; Douros K; Loukou I
Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980112
[TBL] [Abstract][Full Text] [Related]
16. CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare
Lefferts JW; Bierlaagh MC; Kroes S; Nieuwenhuijze NDA; Sonneveld van Kooten HN; Niemöller PJ; Verburg TF; Janssens HM; Muilwijk D; van Beuningen SFB; van der Ent CK; Beekman JM
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833986
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
Stekolchik E; Saul D; Chidekel A
Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
[TBL] [Abstract][Full Text] [Related]
18. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M
Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357
[TBL] [Abstract][Full Text] [Related]
19. The role of modulators in cystic fibrosis related diabetes.
Merjaneh L; Hasan S; Kasim N; Ode KL
J Clin Transl Endocrinol; 2022 Mar; 27():100286. PubMed ID: 34917484
[TBL] [Abstract][Full Text] [Related]
20. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
